Entera Bio announced that it has been selected to present data for its investigational program EB612 at the Endocrine Society ENDO 2024 Annual Meeting which will be held on June 1-4, 2024 in Boston, Massachusetts. The EB612 program is being developed by Entera to provide the first oral PTH(1-34) tablet peptide replacement therapy for patients suffering from hypoparathyroidism. Hypoparathyroidism is characterized by deficient PTH production, hypocalcemia and hyperphosphatemia. Standard treatments include several daily administrations of high dose oral calcium supplements and calcitriol, which are often associated with ectopic calcification, including nephrocalcinosis and renal failure. Late stage investigational PTH replacement treatments include TransCon PTH by Ascendis Pharma A/S and eneboparatide by Amolyt Pharma. Both these modalities require patients to administer injections every day.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ENTX:
- Entera Bio to Present Phase 1 Data from First-in-Class, PTH(1-34) Peptide Tablets (EB612) for the Treatment of Hypoparathyroidism at ENDO 2024
- Entera Bio Releases Crucial Financial Information Update
- Entera Bio Reports Q1 2024 Financial Results and Provides Business Updates
- Biotech Alert: Searches spiking for these stocks today
- Entera Bio publishes data on oral PTH peptide tablet for osteoporosis in JBMR
Questions or Comments about the article? Write to editor@tipranks.com